BiotechTube

trofinetide

Phase 3Terminated
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rett Syndrome

Conditions

Rett Syndrome

Trial Timeline

Nov 8, 2020 → Jun 30, 2023

NCT ID
NCT04776746

About trofinetide

trofinetide is a phase 3 stage product being developed by Acadia Pharmaceuticals for Rett Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT04776746. Target conditions include Rett Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (4)

NCT IDPhaseStatus
NCT04988867Phase 2/3Terminated
NCT04776746Phase 3Terminated
NCT04279314Phase 3Completed
NCT04181723Phase 3Completed

Competing Products

20 competing products in Rett Syndrome

See all competitors
ProductCompanyStageHype Score
Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved
85
Esomeprazole + LansoprazoleAstraZenecaApproved
85
Esomeprazole MagnesiumAstraZenecaApproved
85
AZD5213 and placeboAstraZenecaPhase 2
52
fingolimod (FTY720)NovartisPhase 1/2
41
PF-03654746 + Placebo + Placebo + PF-03654746PfizerPhase 2
51
AripiprazoleBristol Myers SquibbPre-clinical
22
NBI-98854Neurocrine BiosciencesPhase 2
49
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 2
49
NBI-98854Neurocrine BiosciencesPhase 1
30
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
Abobotulinum toxin AIpsenPre-clinical
20
GWP42003-P + PlaceboJazz PharmaceuticalsPhase 3
74
GWP42003-PJazz PharmaceuticalsPhase 3
74
TrofinetideAcadia PharmaceuticalsPhase 3
72
TrofinetideAcadia PharmaceuticalsPhase 2/3
60

Other Products from Acadia Pharmaceuticals

PimavanserinApproved
80
PimavanserinApproved
80
PimavanserinApproved
80
PimavanserinPhase 3
72
Pimavanserin tartrate (ACP-103) + Pimavanserin tartrate (ACP-103) + PlaceboPhase 3
72